23andMe: Genetic Testing or Bioprospecting?
This week, the Harvard Program on Science, Technology, & Society held the latest installment in its Science and Democracy Lecture Series, featuring Anne Wojcicki, the co-founder and CEO of 23andMe, a direct-to-consumer genetic testing company.
The lecture, called "Deleterious Me," combined an account of 23andMe's practices, and the challenges they've faced, with a blend of optimism and fatalism about the future (and future ubiquity) of personalized medicine, affordable biotechnology, and patient- (or consumer-) driven innovation in the health care industry.
Many in attendance, not least a few of the scholars on the panel tasked with responding to the address, found Wojcicki's boosterism unpalatable. In particular, a line of critique running through the commentary centered on the nature of the relationship between the two stated missions of 23andMe: one individualistic, one collectivist.
On the one hand, Wojcicki highlighted her desire to empower consumer-patien…
The lecture, called "Deleterious Me," combined an account of 23andMe's practices, and the challenges they've faced, with a blend of optimism and fatalism about the future (and future ubiquity) of personalized medicine, affordable biotechnology, and patient- (or consumer-) driven innovation in the health care industry.
Many in attendance, not least a few of the scholars on the panel tasked with responding to the address, found Wojcicki's boosterism unpalatable. In particular, a line of critique running through the commentary centered on the nature of the relationship between the two stated missions of 23andMe: one individualistic, one collectivist.
On the one hand, Wojcicki highlighted her desire to empower consumer-patien…